Rallybio Corp (RLYB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US75120L2097
Rallybio Corp financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 858,000.00 USD |
| Operating income | -33.06 m USD |
| EBIT | -8.98 m USD |
| Net income | -8.98 m USD |
| Diluted EPS – continuing operations | -1.59 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
More stocks
- Bonraybio Co., Ltd. (6955.TW)
- Swvl Holdings Corp (SWVL)
- Proficient Auto Logistics, Inc (PAL)
- Enterprise Group Inc (E.TO)
- AAC Clyde Space AB (publ) (AAC.ST)
- Leadtrend Technology Corp (3588.TW)
- Chateau International Development Co Ltd (2722.TW)
- Minaurum Silver Inc. (MGG.V)
- Prolific Technology (6233.TWO)
- Daehan Synthet (003830.KS)
- Selvita S.A. (SLV.WA)
- IBKS No. 16 Special Purpose Acquisition Co. Ltd. (388790.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.